- Home
- MRAM vs NTHI Comparison
MRAM vs NTHI Comparison
Compare MRAM & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRAM
- NTHI
- Stock Information
- Founded
- MRAM 2008
- NTHI 2008
- Country
- MRAM United States
- NTHI United States
- Employees
- MRAM N/A
- NTHI N/A
- Industry
- MRAM Semiconductors
- NTHI Biotechnology: Pharmaceutical Preparations
- Sector
- MRAM Technology
- NTHI Health Care
- Exchange
- MRAM Nasdaq
- NTHI Nasdaq
- Market Cap
- MRAM 114.4M
- NTHI 110.9M
- IPO Year
- MRAM 2016
- NTHI N/A
- Fundamental
- Price
- MRAM $6.75
- NTHI $4.75
- Analyst Decision
- MRAM Strong Buy
- NTHI
- Analyst Count
- MRAM 1
- NTHI 0
- Target Price
- MRAM $8.00
- NTHI N/A
- AVG Volume (30 Days)
- MRAM 216.5K
- NTHI 269.9K
- Earning Date
- MRAM 07-30-2025
- NTHI 01-01-0001
- Dividend Yield
- MRAM N/A
- NTHI N/A
- EPS Growth
- MRAM N/A
- NTHI N/A
- EPS
- MRAM N/A
- NTHI N/A
- Revenue
- MRAM $49,110,000.00
- NTHI $79,990.00
- Revenue This Year
- MRAM $9.48
- NTHI N/A
- Revenue Next Year
- MRAM $12.85
- NTHI N/A
- P/E Ratio
- MRAM N/A
- NTHI N/A
- Revenue Growth
- MRAM N/A
- NTHI 13.52
- 52 Week Low
- MRAM $4.34
- NTHI $3.20
- 52 Week High
- MRAM $7.02
- NTHI $25.00
- Technical
- Relative Strength Index (RSI)
- MRAM 62.00
- NTHI N/A
- Support Level
- MRAM $6.70
- NTHI N/A
- Resistance Level
- MRAM $6.94
- NTHI N/A
- Average True Range (ATR)
- MRAM 0.24
- NTHI 0.00
- MACD
- MRAM 0.03
- NTHI 0.00
- Stochastic Oscillator
- MRAM 74.30
- NTHI 0.00
About MRAM Everspin Technologies Inc.
Everspin Technologies Inc is a provider of Magnetoresistive Random Access Memory (MRAM) products. Its portfolio of MRAM technologies, including Toggle MRAM and Spin-transfer Torque MRAM (STT-MRAM), delivers superior performance, persistence, and reliability in non-volatile memories that transform how mission-critical data is protected against power loss. The company derives revenue from the sale of MRAM-based products in discrete unit form, licenses of and royalties on MRAM and magnetic sensor technology, the sale of backend foundry services, and design services to third parties. It recognizes revenue in three primary geographic regions; North America; Europe, the Middle East, and Africa (EMEA) and Asia-Pacific (APAC).
About NTHI NeOnc Technologies Holdings Inc. Common Stock
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration ("FDA").